BTK and Sepsis: We report here, for the first time, that (a) activation of BTK is associated activation of NF-κB in septic hearts, and (b) inhibition of BTK activity with ibrutinib or acalabrutinib reduces both the activation of NF-κB in septic hearts and the cardiac dysfunction caused by sepsis.